Novartis gets FDA breakthrough status for Tafinlar, Mekinist combination

ZURICH (Reuters) - Novartis on Monday said the U.S. Food and Drug Administration has granted breakthrough therapy status to the combination of Tafinlar and Mekinist to treat patients with BRAF V600-positive stage III melanoma following surgery.